UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Scientific reports, 2024-07, Vol.14 (1), p.17515-12, Article 17515

2024

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

European journal of clinical pharmacology, 2012-03, Vol.68 (3), p.249-258

2012

Volltextzugriff (PDF)

Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler

Chest, 2013-12, Vol.144 (6), p.1795-1802

2013

Volltextzugriff (PDF)

Once-Daily Evening Dosing of Mometasone Furoate Administered via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis

Chest, 2010-01, Vol.137 (1), p.115-121

2010

Volltextzugriff (PDF)

Mometasone Furoate Has Minimal Effects on the Hypothalamic-Pituitary-Adrenal Axis When Delivered at High Doses

Chest, 2000-12, Vol.118 (6), p.1538-1546

2000

Volltextzugriff (PDF)

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects

Journal of clinical pharmacology, 2006-03, Vol.46 (3), p.321-327

2006

Volltextzugriff (PDF)

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

European journal of clinical pharmacology, 2012-11, Vol.68 (11), p.1501-1508

2012

Volltextzugriff (PDF)

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar

Journal of clinical pharmacology, 2013-05, Vol.53 (5), p.540-549

2013

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

European journal of clinical pharmacology, 2012-07, Vol.68 (7), p.1049-1056

2012

Volltextzugriff (PDF)

Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure

Clinical science (1979), 1996-09, Vol.91 (3), p.283-291

1996

Volltextzugriff (PDF)

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects

International journal of clinical pharmacology and therapeutics, 2014-10, Vol.52 (10), p.889-899

2014

Volltextzugriff (PDF)

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

European journal of clinical pharmacology, 2012-03, Vol.68 (3), p.291-300

2012

Volltextzugriff (PDF)

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects

European journal of clinical pharmacology, 2011-05, Vol.67 (5), p.483-492

2011

Volltextzugriff (PDF)

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe

Clinical therapeutics, 2001-06, Vol.23 (6), p.871-885

2001

Volltextzugriff (PDF)

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease

International journal of chronic obstructive pulmonary disease, 2013-01, Vol.8 (default), p.107-116

2013

Volltextzugriff (PDF)

An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects

Clinical pharmacology in drug development, 2014-05, Vol.3 (3), p.229-234

2014

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

Circulation (New York, N.Y.), 2001-07, Vol.104 (4), p.406-411

2001

Volltextzugriff (PDF)

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

Current medical research and opinion, 2004-08, Vol.20 (8), p.1197

2004

Volltextzugriff (PDF)

Pharmacodynamic interaction between ezetimibe and rosuvastatin

Current medical research and opinion, 2004-08, Vol.20 (8), p.1185-1195

2004

Volltextzugriff (PDF)

Interaction of Single-Dose Ezetimibe and Steady-State Cyclosporine in Renal Transplant Patients

Journal of clinical pharmacology, 2006-03, Vol.46 (3), p.328-336

2006

Volltextzugriff (PDF)

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone

Clinical pharmacology in drug development, 2015-01, Vol.4 (1), p.56-62

2015

Volltextzugriff (PDF)

Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device

Clinical pharmacology in drug development, 2014-05, Vol.3 (3), p.222-228

2014

Volltextzugriff (PDF)

The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe

Current medical research and opinion, 2005-08, Vol.21 (8), p.1171-1179

2005

Volltextzugriff (PDF)

Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers

Current medical research and opinion, 2004-09, Vol.20 (9), p.1493-1500

2004

Volltextzugriff (PDF)

Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep

American journal of physiology. Regulatory, integrative and comparative physiology, 1996-08, Vol.271 (2), p.373-R380

1996

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieThe Journal Of Infectious Diseases

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler

Once-Daily Evening Dosing of Mometasone Furoate Administered via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis

Mometasone Furoate Has Minimal Effects on the Hypothalamic-Pituitary-Adrenal Axis When Delivered at High Doses

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease

An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

Pharmacodynamic interaction between ezetimibe and rosuvastatin

Interaction of Single-Dose Ezetimibe and Steady-State Cyclosporine in Renal Transplant Patients

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone

Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device

The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe

Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers

Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep

Aktive Filter

Suchergebnisse filtern